Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-22 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

June 22, 2026 | Edition #BMP-062226

⚡ TL;DR

The Bundibugyo Ebola outbreak in DRC and Uganda has now surpassed 896 confirmed cases and 232 deaths as of June 17, making it the dominant global health emergency of the moment. [1]

Overall mood: grave on the outbreak front, steady elsewhere — food safety alerts pile up, longevity science quietly advances on senescence and the aging epigenome.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of June 17, 2026, a cumulative 896 confirmed cases and 232 confirmed deaths have been reported from DRC, with cross-border transmission continuing into Uganda. [1]
  • WHO declared the Bundibugyo virus disease (BVD) outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026; it does not yet meet the criteria for pandemic emergency per the IHR Emergency Committee. [2] [3]
  • Africa CDC and WHO jointly launched a continental preparedness and response plan on June 5, 2026, targeting a fundraising goal of US$518 million to support African countries in containing spread. [4]
  • WHO released its first comprehensive clinical management guidelines for filovirus disease on June 17, 2026, covering all Ebola types and Marburg virus, timed directly to the active BVD outbreak. [5]
  • WHO convened expert advisory groups on May 28, 2026, to assess candidate treatments and vaccines specifically for Bundibugyo virus; no approved countermeasure yet exists for this strain. [6]
  • CDC activated enhanced Ebola airport entry screening at Washington-Dulles International Airport on May 21, 2026, subsequently expanding that screening to Atlanta's Hartsfield-Jackson. [7] [8]
  • CDC and WHO provided a joint update on June 18, 2026, pairing the Ebola response briefing with World Cup 2026 biosurveillance activation given mass international travel. [9]

HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • The fourth and most recent WHO Disease Outbreak News on the Andes hantavirus cluster (published May 28, 2026) confirms ongoing multi-country spread linked to the M/V Hondius cruise ship, which originally reported cases to WHO on May 2, 2026. [10]
  • As of early May, WHO confirmed 8 total cases including 3 deaths; 5 of 8 cases laboratory-confirmed as Andes hantavirus, a strain known for person-to-person transmission.
  • Over 120 passengers from 23 countries were safely disembarked in Tenerife following coordinated international response; WHO Director-General Tedros personally addressed the people of Tenerife.
  • CDC activated its own hantavirus response tracking and issued daily transcripts through mid-May 2026, noting overall risk to the American public remains extremely low.

MPOX - CLADE IB AND RECOMBINANT STRAIN

  • A December 2025 WHO Disease Outbreak News (DON-587) flagged local clade Ib MPXV transmission among men who have sex with men (MSM) in countries previously reporting only travel-linked cases, signaling geographic expansion.
  • A February 2026 WHO DON-595 documented a newly detected recombinant mpox strain carrying genomic elements of both clade Ib and clade IIb; two cases confirmed, mechanism is natural co-infection allowing genetic exchange.

NIPAH VIRUS - INDIA AND BANGLADESH

  • India reported two laboratory-confirmed Nipah virus (NiV) infections in West Bengal on January 26, 2026; both patients were healthcare workers at the same private hospital in Barasat, North 24 Parganas district, confirmed by National Institute of Virology.
  • Bangladesh separately notified WHO on February 3, 2026, of one confirmed NiV case in Rajshahi Division; the patient developed fever and neurological symptoms on January 21, 2026.

MERS-COV

  • As of December 21, 2025, 19 MERS-CoV cases including 4 deaths were reported globally in 2025; 17 of 19 cases originated in Saudi Arabia, 2 in France; WHO notes no sustained human-to-human transmission detected.

AVIAN INFLUENZA A(H9N2) - ITALY

  • Italy notified WHO on March 21, 2026, of a human H9N2 case in an adult male returning from Senegal; next-generation sequencing confirmed Influenza A(H9N2); this remains a sporadic zoonotic event.

MEASLES - BANGLADESH AND GLOBAL

  • Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases spanning 58 of 64 districts across all 8 divisions as of April 2026, signaling a severe nationwide resurgence.
  • Global context: CDC data released November 2024 recorded 10.3 million measles infections worldwide in 2023, underscoring the scale of vaccination gaps driving these surges.

FOOD-BORNE OUTBREAKS - UNITED STATES (ACTIVE)

  • CDC warns of a Listeria outbreak linked to recalled chicken fettuccine alfredo meals; 17 people have been sickened by the same Listeria strain as of June 19, 2026.
  • CDC issued a June 5, 2026, alert on a Listeria outbreak tied to requesón/soft ricotta cheese; consumers are urged to avoid the implicated product.
  • A Salmonella outbreak linked to pistachio cream has sickened 4 people with the same strand as of June 16, 2026.
  • A Salmonella outbreak linked to eggs was posted by CDC on June 7, 2026, continuing a pattern of egg-associated Salmonella events in 2025-2026.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AND KIDNEY REPAIR

  • A June 14, 2026, Europe PMC study (Mao et al., Ren Fail) finds that the enzyme AMD1, which controls polyamine metabolism, governs whether tubular kidney cells repair themselves or enter senescence after acute kidney injury — pointing to a targetable metabolic checkpoint in aging-related organ decline.

EPIGENETIC AGING AND INTRACRANIAL ANEURYSM RISK

  • A genetic study (Zhang et al., IBRO Neurosci Rep, May 30, 2026) uses Mendelian randomization to link DNA methylation-estimated phenotypes and shorter telomere length to increased risk of intracranial aneurysm, providing causal evidence connecting biological aging pace to cerebrovascular disease.

HANDGRIP STRENGTH AS AGING BIOMARKER

  • A June 15, 2026, prospective parallel cohort study (Liu et al., Glob Health Action) in Chinese and European older adults finds that combined low handgrip strength is independently associated with higher incidence of chronic digestive diseases, reinforcing grip strength as a practical surrogate for musculoskeletal aging.

GUT MICROBIOME AND EARLY LIFE PROGRAMMING

  • Kadyan et al. (Gut Microbes, June 9, 2026) demonstrate in an animal model that maternal diet shapes neonatal gut microbiome composition, with downstream effects on neurometabolic resilience — suggesting longevity trajectories may be set in part before birth.

PREBIOTICS, OBESITY, AND OSTEOARTHRITIS

  • Wang et al. (Gut Microbes, June 2, 2026) use multi-omics to show that prebiotic supplementation alters gut microbiome profiles and modulates physical function and metabolism in adults with obesity and knee osteoarthritis, two major drivers of disability in aging populations.

REDOX BIOLOGY AND AGING BIOMARKERS

  • Ishima et al. (Redox Rep, June 2, 2026) characterize albumin Cys34 oxidation as a dynamic biomarker of systemic redox stress, with polysulfide-mediated homeostatic mechanisms offering a potential intervention point for age-related oxidative damage.
  • Mathias-Netto et al. (Redox Rep, June 11, 2026) detail enzymatic and non-enzymatic oxidation of fibrillar collagen, a key structural protein whose oxidative degradation underpins skin aging, tissue stiffening, and organ fibrosis.

URIC ACID AND NEURODEGENERATION

  • Zhou et al. (Redox Rep, June 4, 2026) show in LPS-induced BV2 cells and a Parkinson's disease mouse model (MPTP-induced) that uric acid alleviates inflammatory responses by inhibiting ferroptosis through the Nrf2 signaling pathway, suggesting a mechanistic link between uric acid metabolism and neuronal survival.

REPRODUCTIVE AGING

  • A narrative review (Yang et al., J Obstet Gynaecol, June 9, 2026) synthesizes evidence on delayed childbearing and reproductive aging, noting accelerated ovarian reserve decline and rising rates of age-related chromosomal errors in women deferring pregnancy beyond their mid-30s.

💊 NEW CURES & APPROVALS

(Note: openFDA supplemental approvals in the data lack precise dates; items reflect active supplement actions recorded in Drugs@FDA.)

KEYTRUDA (PEMBROLIZUMAB) - MERCK SHARP DOHME

  • Merck's PD-1 checkpoint inhibitor pembrolizumab (Keytruda, BLA-125514) received a supplemental approval action; pembrolizumab works by blocking the PD-1 receptor on T cells to unleash anti-tumor immune activity across multiple cancer indications.

SKYRIZI (RISANKIZUMAB-RZAA) - ABBVIE INC

  • AbbVie's IL-23 inhibitor risankizumab-rzaa (Skyrizi) received supplemental approval actions on two separate BLA filings (BLA-761262 and BLA-761105), covering its use in inflammatory conditions including plaque psoriasis and inflammatory bowel disease.

WELIREG (BELZUTIFAN) - MERCK SHARP DOHME

  • Merck's HIF-2alpha inhibitor belzutifan (Welireg, NDA-215383) received a supplemental approval; it targets hypoxia-inducible factor 2-alpha, disrupting tumor angiogenesis and metabolism in VHL disease-associated and renal cell carcinoma settings.

RINVOQ LQ (UPADACITINIB) - ABBVIE

  • AbbVie's JAK-1 selective inhibitor upadacitinib liquid formulation (Rinvoq LQ, NDA-218347) received a supplemental approval, relevant for patients including pediatric or those unable to swallow tablets, across inflammatory indications.

TZIELD (TEPLIZUMAB-MZWV) - PROVENTION BIO INC

  • Provention Bio's anti-CD3 monoclonal antibody teplizumab-mzwv (Tzield, BLA-761183) received a supplemental approval action; teplizumab delays onset of clinical type 1 diabetes by modulating autoreactive T cells in at-risk individuals.

BOSUTINIB MONOHYDRATE - ALEMBIC (GENERIC)

  • Alembic received a tentative approval for generic bosutinib monohydrate (ANDA-209543), a BCR-ABL1 tyrosine kinase inhibitor used in chronic myelogenous leukemia (CML), expanding affordable access to this targeted therapy.

REXTOVY (NALOXONE HYDROCHLORIDE) - AMPHASTAR PHARMACEUTICALS

  • Amphastar's naloxone hydrochloride formulation Rextovy (NDA-208969) received a supplemental approval; naloxone rapidly reverses opioid overdose by competitively binding mu-opioid receptors.

🧪 CLINICAL TRIALS

AI AND COGNITIVE AGING - VIRTUAL REALITY DRIVING ASSESSMENT

  • A new ClinicalTrials.gov study (NCT07656389, registered June 18, 2026) uses AI-based analysis of older adults and mild cognitive impairment (MCI) patients during virtual reality driving tasks to predict cognitive capacity, targeting the "look-but-fail-to-see" failure mode linked to increased crash risk in aging drivers.

VIRTUAL REALITY FOR FALLS PREVENTION IN OLDER ADULTS

  • NCT07655882 (registered June 18, 2026) is testing whether VR-based interactive exercise training outperforms traditional physical therapy in improving gait and balance in older adults, directly addressing falls as a primary aging-associated cause of disability and death.

TEMPERATURE MANAGEMENT AND POST-SURGICAL COGNITIVE DECLINE IN ELDERLY CANCER PATIENTS

  • NCT07655687 (June 18, 2026) targets delayed neurocognitive recovery (dNCR) after major cancer surgery in older patients using targeted temperature management, acknowledging that aging populations are disproportionately affected by postoperative cognitive complications.

SIROLIMUS FOR SLE-ASSOCIATED IMMUNE THROMBOCYTOPENIA

  • NCT07657793 (June 18, 2026) is testing sirolimus (an mTOR inhibitor with known longevity-pathway relevance) added to standard-of-care corticosteroids and hydroxychloroquine in adults aged 18-65 with systemic lupus erythematosus-associated immune thrombocytopenia, also assessing long-term safety.

SUCRALOSE, SUCROSE, AND GLUCOSE METABOLISM - SUCROMET TRIAL

  • NCT07656298 (June 18, 2026) is a nutritional intervention trial evaluating how low and high doses of sucrose and sucralose affect insulin resistance and fasting plasma glucose in adults aged 18-65 across normal weight, overweight, and obese subgroups.

ORFORGLIPRON IN ADOLESCENT OBESITY - LILLY

  • NCT06672939 (June 18, 2026) evaluates Eli Lilly's oral GLP-1 receptor agonist orforglipron (LY3502970) versus placebo in adolescents with obesity or overweight plus comorbidities, part of Lilly's Master Protocol J4M-MC-PWMP, expanding GLP-1 science into younger age brackets.

HEART FAILURE MULTI-OMICS - MAP-HEART

  • NCT06280820 (updated June 18, 2026) is conducting multi-scale phenotypic analysis of blood and tissue samples in heart failure patients to understand disease development mechanisms across the more than 6.5 million Americans living with HF.

LOSARTAN TO REDUCE RADIATION-INDUCED FIBROSIS IN BREAST CANCER

  • NCT05637216 (June 18, 2026) is testing FDA-approved TGF-beta-1 blocker losartan to reduce radiation-induced fibrosis in breast and lung tissue of breast cancer patients, leveraging losartan's anti-fibrotic mechanism as a secondary age-relevant endpoint.

📢 PUBLIC HEALTH

ACIP JUNE 25-26, 2026 MEETING

  • CDC's Advisory Committee on Immunization Practices concluded its June 25-26, 2026, meeting and released a joint statement; agenda and presentations are posted online, though specific votes were not detailed in available summaries.

NEW WORLD SCREWWORM - CDC EMERGENCY OPERATIONS CENTER

  • CDC activated its Emergency Operations Center on June 12, 2026, for New World Screwworm (Cochliomyia hominivorax) response, a parasitic fly whose larvae infest living tissue of warm-blooded animals and, rarely, humans.

DRUG-RESISTANT BACTERIA ON THE RISE

  • A CDC report released September 23, 2025, documented a dramatic increase in dangerous drug-resistant bacteria in the United States, underscoring that antimicrobial resistance remains a parallel long-term health threat alongside infectious outbreaks.

INFANT BOTULISM AND NARA ORGANICS FORMULA

  • CDC issued a June 13, 2026, outbreak update urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to an infant botulism cluster; the outbreak was first flagged in December 2025.

MORINGA LEAF PRODUCTS - SALMONELLA ALERT ONGOING

  • CDC's May 27, 2026, alert (updated) flagged a growing number of Salmonella illnesses and outbreaks across multiple distinct clusters all linked to moringa leaf products including powdered supplements and capsules; as of January 29, 2026, 65 people across 28 states had been sickened in the moringa leaf supplement cluster alone.

UNSAFE FOOD GLOBAL BURDEN

  • A June 3, 2026, WHO report estimates unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under 5 face nearly three times the illness risk from contaminated food compared to older populations.

CDC BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed 1 million voluntary air travel participants as of January 30, 2026, strengthening the agency's capacity to detect novel pathogens at international entry points.

BIOMED PULSE is informational only and does not constitute medical advice. Sources: WHO, CDC, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC/PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
  6. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda and CDC's World Cup 2026(TM) ac — CDC Newsroom
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260622-02-v8 · 2026-06-22 02:02 UTC

Read next